CN1166651C - 具有抗炎和抗肿瘤作用r-双或糖苯丙异硒唑取代化合物 - Google Patents

具有抗炎和抗肿瘤作用r-双或糖苯丙异硒唑取代化合物 Download PDF

Info

Publication number
CN1166651C
CN1166651C CNB011186666A CN01118666A CN1166651C CN 1166651 C CN1166651 C CN 1166651C CN B011186666 A CNB011186666 A CN B011186666A CN 01118666 A CN01118666 A CN 01118666A CN 1166651 C CN1166651 C CN 1166651C
Authority
CN
China
Prior art keywords
ketone
weight
parts
selenazoles
isoselenazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB011186666A
Other languages
English (en)
Chinese (zh)
Other versions
CN1390837A (zh
Inventor
曾慧慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COLLEGE OF PHARMACY BEIJING UNIV
Original Assignee
COLLEGE OF PHARMACY BEIJING UNIV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CNB011186666A priority Critical patent/CN1166651C/zh
Application filed by COLLEGE OF PHARMACY BEIJING UNIV filed Critical COLLEGE OF PHARMACY BEIJING UNIV
Priority to EP02742662A priority patent/EP1422225B1/en
Priority to CA2450087A priority patent/CA2450087C/en
Priority to PCT/CN2002/000412 priority patent/WO2003095436A1/zh
Priority to JP2004503452A priority patent/JP4500672B2/ja
Priority to US10/479,883 priority patent/US7495019B2/en
Priority to AT02742662T priority patent/ATE540030T1/de
Priority to RU2003134946/04A priority patent/RU2324688C2/ru
Priority to AU2002346271A priority patent/AU2002346271A1/en
Priority to ES02742662T priority patent/ES2378983T3/es
Publication of CN1390837A publication Critical patent/CN1390837A/zh
Application granted granted Critical
Publication of CN1166651C publication Critical patent/CN1166651C/zh
Priority to US12/349,829 priority patent/US8609702B2/en
Priority to US12/351,100 priority patent/US7820829B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
    • C07D293/10—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D293/12—Selenazoles; Hydrogenated selenazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB011186666A 2001-06-08 2001-06-08 具有抗炎和抗肿瘤作用r-双或糖苯丙异硒唑取代化合物 Expired - Fee Related CN1166651C (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CNB011186666A CN1166651C (zh) 2001-06-08 2001-06-08 具有抗炎和抗肿瘤作用r-双或糖苯丙异硒唑取代化合物
AU2002346271A AU2002346271A1 (en) 2001-06-08 2002-06-10 Benzoisoselenazole derivatives with anti-inflammation, antivirus and anti-thrombosis activity and their use
PCT/CN2002/000412 WO2003095436A1 (en) 2001-06-08 2002-06-10 Benzoisoselenazole derivatives with anti-inflammation, antivirus and anti-thrombosis activity and their use
JP2004503452A JP4500672B2 (ja) 2001-06-08 2002-06-10 抗炎症、抗ウイルスおよび抗血栓症活性を有するベンゾイソセレンアゾール誘導体ならびにそれらの使用
US10/479,883 US7495019B2 (en) 2001-06-08 2002-06-10 Benzoisoselenazole derivatives with anti-inflammation, antivirus and antithrombosis activity and their use
AT02742662T ATE540030T1 (de) 2001-06-08 2002-06-10 Benzoisoselenazolderivate mit entzündungshemmender, antineoplastischer und antithrombotischer wirkung und deren verwendungen
EP02742662A EP1422225B1 (en) 2001-06-08 2002-06-10 Benzoisoselenazole derivatives with anti-inflammation, antineoplastic and anti-thrombosis activity and their use
CA2450087A CA2450087C (en) 2001-06-08 2002-06-10 Benzisoselenazolonyl derivatives having antineoplastic, anti-inflammatory and antithrombotic activities as well as their use
ES02742662T ES2378983T3 (es) 2001-06-08 2002-06-10 Derivados de benzoisoselenazolonilo que tienen actividades antineoplásica, antiinflamatoria y antitrombótica y su uso
RU2003134946/04A RU2324688C2 (ru) 2001-06-08 2002-06-10 Производные бисбензизоселеназолонила с противоопухолевым, противовоспалительным и антитромботическим действием и их применение
US12/349,829 US8609702B2 (en) 2001-06-08 2009-01-07 Benzoisoselenazole derivatives with anti-inflammation, antivirus and antithrombosis activity and their use
US12/351,100 US7820829B2 (en) 2001-06-08 2009-01-09 Bisbenzisoselenazolonyl derivatives having antineoplastic, anti-inflammatory and antithrombotic activities as well as their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB011186666A CN1166651C (zh) 2001-06-08 2001-06-08 具有抗炎和抗肿瘤作用r-双或糖苯丙异硒唑取代化合物

Publications (2)

Publication Number Publication Date
CN1390837A CN1390837A (zh) 2003-01-15
CN1166651C true CN1166651C (zh) 2004-09-15

Family

ID=4663351

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB011186666A Expired - Fee Related CN1166651C (zh) 2001-06-08 2001-06-08 具有抗炎和抗肿瘤作用r-双或糖苯丙异硒唑取代化合物

Country Status (10)

Country Link
US (2) US7495019B2 (https=)
EP (1) EP1422225B1 (https=)
JP (1) JP4500672B2 (https=)
CN (1) CN1166651C (https=)
AT (1) ATE540030T1 (https=)
AU (1) AU2002346271A1 (https=)
CA (1) CA2450087C (https=)
ES (1) ES2378983T3 (https=)
RU (1) RU2324688C2 (https=)
WO (1) WO2003095436A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820829B2 (en) * 2001-06-08 2010-10-26 Peking University Bisbenzisoselenazolonyl derivatives having antineoplastic, anti-inflammatory and antithrombotic activities as well as their use
CN100554255C (zh) * 2004-05-31 2009-10-28 北京大学 苯并异硒唑酮衍生物及其制备方法与应用
CN1990475B (zh) * 2005-12-29 2011-09-07 曾慧慧 取代苯并异硒唑酮类化合物及其用途
US20090005422A1 (en) * 2006-05-22 2009-01-01 Thioredoxin Systems Ab Bacterial thioredoxin reductase inhibitors and methods for use thereof
CN101016319B (zh) * 2007-02-13 2010-08-04 中国海洋大学 苯并异硒唑酮氨基糖衍生物及其制备方法和应用
CN101781283B (zh) * 2009-01-16 2014-04-23 凯熙医药（武汉）股份有限公司 硫氧还蛋白还原酶抑制剂化合物及其制备方法和其应用
MD4014C2 (ro) * 2009-04-23 2010-09-30 Татьяна ГУЦУЛ Complecşi polioxometalaţi cu activitate antitumorală
CN101921303A (zh) * 2009-06-09 2010-12-22 曾慧慧 苯并异硒唑酮二氟胞苷类化合物及其制备方法和其用途
CN102453050B (zh) * 2010-11-03 2015-01-07 成都云克药业有限责任公司 一种二膦酸化合物及其制备方法
AU2013202104B2 (en) * 2012-01-13 2015-11-26 Celgene Corporation Biomarkers for the treatment of hepatocellular carcinoma
CN103483291B (zh) * 2012-06-14 2015-08-12 沈阳药科大学 4,5-二芳基-1,3-硒唑类化合物及其制备方法和用途
CN104177312B (zh) * 2013-05-27 2018-02-13 黄英武 一种含硒化合物及其医药用途
CN105277699B (zh) * 2014-07-21 2017-05-03 武汉尚宜康健科技有限公司 测试试剂在制备评价临床肿瘤患者临床治疗监测的药品中的应用
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
CN110856717A (zh) * 2018-08-06 2020-03-03 上海元熙医药科技有限公司 一种肿瘤免疫调节剂及其用途
ES3058229T3 (en) 2019-06-24 2026-03-09 Shanghai Yuanxi Medicine Corp Crystal form of 1,4-[bis(1,2-benzisoselenazol-3(2h)-one)]butane, preparation method therefor, and application thereof
KR20230002109A (ko) * 2021-06-29 2023-01-05 (주)라이프신약 셀레늄 화합물을 유효성분으로 포함하는 노화세포 제거용 조성물
WO2023277584A1 (ko) * 2021-06-29 2023-01-05 (주)라이프신약 셀레늄 화합물을 유효성분으로 포함하는 노화세포 제거용 조성물
CN116891443B (zh) * 2023-09-08 2023-12-01 潍坊医学院 一种异吲哚-1-酮衍生物及其制备方法、应用
WO2025169231A1 (en) * 2024-02-09 2025-08-14 Indian Institute Of Science Organoselenium compounds, preparation and implementations thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3027075A1 (de) * 1980-07-17 1982-02-18 A. Nattermann & Cie GmbH, 5000 Köln Benzisoselenazolone, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4531001A (en) * 1982-03-23 1985-07-23 Brigham Young University 2-β-D-ribofuranosylselenazole-4-carboxamide compounds
DE3226284A1 (de) * 1982-07-14 1984-01-19 A. Nattermann & Cie GmbH, 5000 Köln Neue benzisoselenazolone, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3407511A1 (de) * 1984-03-01 1985-09-05 A. Nattermann & Cie GmbH, 5000 Köln Benzisoselenazolthione, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3663139D1 (en) * 1985-04-12 1989-06-08 Nattermann A & Cie Diseleno-bis-benzamides of primary and secondary amines, processes for their production and pharmaceutical preparations containing them
DE3670635D1 (de) * 1985-04-27 1990-05-31 Nattermann A & Cie Neue benzisoselenazolonyl-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DE3638124C2 (de) * 1986-11-08 1996-09-05 Nattermann A & Cie Neue pharmazeutische Verwendung von Ebselen
US4778814A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of treating ocular allergy by topical application of a 2-substituted-1,2-benzisoselenazol-3(2H)-one
DE3827093A1 (de) * 1988-08-10 1990-02-15 Nattermann A & Cie Verfahren zur herstellung von hochreinem ebselen
US5385726A (en) * 1990-08-06 1995-01-31 Rhone-Poulenc Rorer Gmbh Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one
DE4024885C2 (de) * 1990-08-06 2002-07-18 Nattermann A & Cie Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
DE4445966A1 (de) * 1994-12-22 1996-06-27 Agfa Gevaert Ag Fotografisches Silberhalogenidmaterial
CN1110489C (zh) * 1998-11-11 2003-06-04 中国医学科学院药物研究所 苯并异硒唑酮磺酰胺衍生物及其制法和其在制备药物中的应用
US20040047852A1 (en) * 2001-03-02 2004-03-11 Kennedy Thomas Preston Method of treating cancer

Also Published As

Publication number Publication date
AU2002346271A1 (en) 2003-11-11
US7495019B2 (en) 2009-02-24
RU2003134946A (ru) 2005-06-10
CN1390837A (zh) 2003-01-15
US20090117204A1 (en) 2009-05-07
EP1422225A4 (en) 2004-10-20
CA2450087C (en) 2012-08-07
US20050014801A1 (en) 2005-01-20
EP1422225B1 (en) 2012-01-04
JP2005519991A (ja) 2005-07-07
JP4500672B2 (ja) 2010-07-14
CA2450087A1 (en) 2003-11-20
RU2324688C2 (ru) 2008-05-20
US8609702B2 (en) 2013-12-17
ES2378983T3 (es) 2012-04-19
EP1422225A1 (en) 2004-05-26
ATE540030T1 (de) 2012-01-15
WO2003095436A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
CN1166651C (zh) 具有抗炎和抗肿瘤作用r-双或糖苯丙异硒唑取代化合物
Menchikov et al. Biological activity of organogermanium compounds (a review)
Mourad et al. Novel HDAC/tubulin dual inhibitor: Design, synthesis and docking studies of α-phthalimido-chalcone hybrids as potential anticancer agents with apoptosis-inducing activity
PT93743A (pt) Processo para a preparacao de derivados organicos fosforados com actividade antivirus
FR2511685A1 (fr) Complexe platine-diamine, procede d'obtention, application d'un tel complexe pour l'obtention d'un medicament pour le traitement du cancer et medicament ainsi obtenu
JP2002530396A (ja) スカベンジャー化合物
WO2019063002A1 (zh) 苯烯莫德的晶型及其用途与制备方法
CN101020654A (zh) 抗肿瘤化合物及其制备方法
Tezcan et al. Benzimidazolium salts bearing the trifluoromethyl group as organofluorine compounds: Synthesis, characterization, crystal structure, in silico study, and inhibitory profiles against acetylcholinesterase and α‐glycosidase
CN112921345A (zh) 一种硫代磷酸酯类化合物的直接电化学合成方法
Ngaini et al. Synthesis and molecular design of mono aspirinate thiourea-azo hybrid molecules as potential antibacterial agents
CN111732565B (zh) 一种蛇床子素酯类化合物及其应用
CN113559106A (zh) 白桦脂酮酸衍生物在制备治疗神经系统疾病药物中的应用
Garg et al. Synthesis of novel α-carboxylate-β-bismethylsulfanyl pyrazolyl Schiff base derivatives: Targeting DNA gyrase in antibacterial activity
CN112142819A (zh) 白桦脂酸衍生物在制备抗肿瘤药物中的应用
Fang et al. Synthesis of phthalide derivatives and evaluation on their antiplatelet aggregation and antioxidant activities
Liu et al. Crystal structures, antioxidation and DNA binding properties of Yb (III) complexes with Schiff-base ligands derived from 8-hydroxyquinoline-2-carbaldehyde and four aroylhydrazines
Kececi Sarıkaya et al. Novel Tricyclo [4.2. 1] Nonane and Bicyclo [2.2. 1] Heptane Derivatives: Synthesis, in Vitro Biological Activities and in Silico Studies
Jahandar Lashaki et al. Ag/KF/CP@ MWCNTs Catalyzed Green Synthetic Pathway for Bio-Active New Thiazolopyrimidines and Oxazolopyrimidines
CN110590759A (zh) 一种水相合成含三氟甲基噻吩基非对称双吲哚化合物的新方法
CA1313667C (en) Indole alkaloid composition and their methods of use
Roberts et al. Procainamide hydroxylamine lymphocyte toxicity—I. Evidence for participation by hemoglobin
Lu et al. Synthesis and antitumor activity of new series of isopimaric heterocyclic sulfonamides derivatives
Nguyen et al. Crystallographic and computational characterization and in silico target fishing of six aromatic and aliphatic sulfonamide derivatives
WO2022227923A1 (zh) 十六烷氨丁三醇化合物、合成方法及其在抗肿瘤、抗真菌方面的应用

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040915

Termination date: 20200608

CF01 Termination of patent right due to non-payment of annual fee